Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Contineum Therapeutics, Inc. Class A ( (CTNM) ) has issued an announcement.
On June 26, 2025, Contineum Therapeutics, Inc. held its 2025 Annual Meeting of Stockholders virtually. During the meeting, stockholders elected three Class I directors to serve until the 2028 Annual Meeting and ratified the appointment of Ernst & Young LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2025.
The most recent analyst rating on (CTNM) stock is a Buy with a $25.00 price target. To see the full list of analyst forecasts on Contineum Therapeutics, Inc. Class A stock, see the CTNM Stock Forecast page.
Spark’s Take on CTNM Stock
According to Spark, TipRanks’ AI Analyst, CTNM is a Underperform.
Contineum Therapeutics, Inc. receives a low stock score due to significant financial struggles, including a lack of revenue and negative profitability. The technical analysis reveals a bearish trend, and the valuation is weak with a negative P/E ratio. While there are some positives in terms of debt reduction and cash reserves, these are overshadowed by the company’s operational challenges and weak market momentum.
To see Spark’s full report on CTNM stock, click here.
More about Contineum Therapeutics, Inc. Class A
Average Trading Volume: 108,290
Technical Sentiment Signal: Strong Sell
Current Market Cap: $118.8M
For a thorough assessment of CTNM stock, go to TipRanks’ Stock Analysis page.